Can-Fite BioPharma financials at a glance

+ Portfolio

The revenue of Can-Fite BioPharma is reported as 0.0008 billion New Shekels in the fiscal year 2023. The earnings were -0.04 New Shekels per share in 2023, which was 60 higher than 2021. And about -1.0E-5 billion New Shekels are reported as free cash flow in the financials of Can-Fite BioPharma 2023. No dividends were paid to the shareholders of the Can-Fite BioPharma stock TASE:CANF in the financial year 2023.

₪0.81M

Revenue

₪-0.04

Earnings Per Share

100.00%

Gross Margin %

₪0.00M

Free Cash Flow

Revenue

0.81

Earnings Per Share

-0.04

Gross Margin %

100.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017
Rev.	Revenue	N/A	₪0.81M	₪0.85M	₪0.76M	₪2.03M	₪3.82M	₪0.85M
GM %	Gross Margin %	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-,141.73%	0.00%
EPS	Earnings Per Share	₪-0.07	₪-0.04	₪-0.10	₪-0.13	₪-0.39	₪-0.62	₪-0.52
Div.	Dividends	N/A	₪0.00	₪0.00	₪0.00	₪0.00	₪0.00	₪0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0
Sha.	Shares	N/AM	1,224.84M	815.75M	515.75M	263.18M	44.88M	33.3M
OCF	Operating Cash Flow	N/A	₪0.00M	₪-9.86M	₪0.00M	₪0.00M	₪-4.16M	₪0.00M
FCF	Free Cash Flow	N/A	₪0.00M	₪-9.87M	₪0.00M	₪0.00M	₪-4.19M	₪0.00M
FCFS	Free Cash Flow Per Share	₪-0.07	₪-0.01	₪-0.02	₪-0.03	₪-0.13	₪-0.11	₪-0.28

Can-Fite BioPharma financials at a glance

Financials

Discover